Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 20/20 | 0.66 |
| ▸ | KCNH2 | Q12809 | 12/20 | 0.66 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.57 |
| ▸ | CDK2 | P24941 | 1/20 | 0.57 |
| ▸ | GRK2 | P25098 | 1/20 | 0.57 |
| ▸ | CLK1 | P49759 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23002843 | 0.94 | GSK3B (0.66) | GSK3BKCNH2CCNA2CDK2GRK2 | |
| SCHEMBL15210993 | 0.84 | GSK3B (0.64) | GSK3BKCNH2CCNA2CDK2GRK2 | |
| Hydrochloric Acid SCHEMBL15210481 | 0.83 | GSK3B (0.63) | GSK3BKCNH2CCNA2CDK2GRK2 | |
| SCHEMBL21550499 | 0.81 | GSK3B (0.64) | GSK3BKCNH2CDK2 | |
| SCHEMBL21550494 | 0.81 | GSK3B (0.66) | GSK3BKCNH2 | |
| SCHEMBL17096130 | 0.81 | GSK3B (0.90) | GSK3BKCNH2CCNA2CDK2GRK2 | |
| SCHEMBL21553772 | 0.80 | GSK3B (0.67) | GSK3BKCNH2 | |
| SCHEMBL23002847 | 0.80 | GSK3B (0.62) | GSK3BKCNH2 | |
| SCHEMBL21567914 | 0.80 | GSK3B (1.00) | GSK3BKCNH2GRK2CLK1 | |
| SCHEMBL21550341 | 0.80 | GSK3B (1.00) | GSK3BKCNH2GRK2CLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112135821-B | 1H-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors | 方济各安吉利克化学联合股份有限公司 | 2024-05-31 | — | — | CN | disclosed |
| US-11472795-B2 | 1H-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO—A.C.R.A.F. S.p.A. (IT) | 2022-10-18 | — | — | US | disclosed |
| EP-3790873-B1 | 1H-INDAZOLE-3-CARBOXAMIDE COMPOUNDS AS GLYCOGEN SYNTHASE KINASE 3 BETA INHIBITORS | ACRAF (IT) | 2022-04-27 | — | — | EP | disclosed |
| EP-3790873-A1 | 1H-INDAZOLE-3-CARBOXAMIDE COMPOUNDS AS GLYCOGEN SYNTHASE KINASE 3 BETA INHIBITORS | Aziende Chimiche Riunite Angelini Francesco A.C.R. (IT) | 2021-03-17 | — | — | EP | disclosed |
| US-20210053956-A1 | 1H-INDAZOLE-3-CARBOXAMIDE COMPOUNDS AS GLYCOGEN SYNTHASE KINASE 3 BETA INHIBITORS | AZIENDE CHIMICHE RIUNITE ANGLELINI FRANCESCO - A.C.R.A.F. S.p.A (IT) | 2021-02-25 | — | — | US | disclosed |
| CN-112135821-A | 1H-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors | 方济各安吉利克化学联合股份有限公司 | 2020-12-25 | — | — | CN | disclosed |
| WO-2019215075-A1 | 1H-INDAZOLE-3-CARBOXAMIDE COMPOUNDS AS GLYCOGEN SYNTHASE KINASE 3 BETA INHIBITORS | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO - A.C.R.A.F. S.P.A. (IT) | 2019-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11472795-B2 | 1H-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors | GSK3B, GSK3A, PYGB | GSK3B 1/4885KCNH2 363/4885CCNA2 3364/4885 |
| US-20210053956-A1 | 1H-INDAZOLE-3-CARBOXAMIDE COMPOUNDS AS GLYCOGEN SYNTHASE KINASE 3 BETA INHIBITORS | GSK3B, GSK3A, PYGB | GSK3B 1/4885KCNH2 363/4885CCNA2 3364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.